TSCAN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.55 USD | +3.14% |
|
+1.66% | +46.66% |
Presenter SpeechDavid Southwell (Executives)Good evening, and thank you very much for joining ...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Companyâs lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
8.55
USD
Average target price
12.5
USD
Spread / Average Target
+46.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +46.66% | 452M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- TCRX Stock
- News TScan Therapeutics, Inc.
- Transcript : TScan Therapeutics, Inc. - Special Call
